Delta Variant SARS-CoV-2 infections in pediatric cases during the second wave in India - Yadav, Pragya D.; Kumar, Gunjan; Mukherjee, Aparna; Nyayanit, Dimpal A.; Shete, Anita M.; Sahay, Rima R.; Kumar, Abhinendra; Majumdar, Triparna; Patil, Savita; Pandit, Priyanka; Joshi, Yash; Dudhmal, Manisha; et al. (medRxiv, 2021)
The aim of this study was to identify the SARS-CoV-2 lineages circulating in the pediatric population of India during the second wave of the pandemic. Clinical and demographic details linked with the nasopharyngeal/oropharyngeal swabs (NPS/OPS) collected from SARS-CoV-2 cases (n=583) aged 0-18 year and tested positive by real-time RT-PCR were retrieved from March to June 2021.Symptoms were reported among 37.2% of patients and 14.8% reported to be hospitalized. The E gene CT value had significant statistical difference at the point of sample collection when compared to that observed in the sequencing laboratory. Out of these 512 sequences 372 were VOCs, 51 were VOIs. Most common lineages observed were Delta, followed by Kappa, Alpha and B.1.36, seen in 65.82%, 9.96%, 6.83% and 4.68%, respectively in the study population. Overall, it was observed that Delta strain was the leading cause of SARS-CoV-2 infection in Indian children during the second wave of the pandemic. We emphasize on the need of continuous genomic surveillance in SARS-CoV-2 infection even amongst children.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was conducted with intramural funding for Molecular epidemiological analysis of SARS-CoV-2 is circulating in different regions of India of Indian Council of Medical Research (ICMR) New Delhi, provided to ICMR-National Institute of Virology, Pune.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Human Ethics Committee of ICMR-NIV, Pune, India under project Molecular epidemiological analysis of SARS- CoV-2 circulating in different regions of India (IHEC no. NIV/IEC/Dec/2020/D-6 dated 31 December 2020)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors